Results 121 to 130 of about 8,834,434 (252)

The association between chronic pain and non‐fatal overdose in people who inject drugs: Longitudinal cohort study in Montreal, Canada, 2017 to 2025

Addiction, EarlyView.
Abstract Background and aims The prevalence of chronic pain is elevated among people who inject drugs. Chronic pain may motivate drug use, potentially increasing the risk of non‐fatal overdose. We aimed to estimate the association between chronic pain and non‐fatal overdose in people who inject drugs.
Sarah Larney, Geng Zang, Harika Dasari, M. Gabrielle Pagé, Farzaneh Vakili, Adelina Artenie, Valérie Martel‐Laferrière, Nanor Minoyan, Sasha Udhesister, Julie Bruneau   +9 more
wiley   +1 more source

Multi-level barriers and facilitators to buprenorphine use in Ontario, Canada: a qualitative study using the theoretical domains framework

Addiction Science & Clinical Practice
Background Few studies have systematically examined the barriers and facilitators to buprenorphine uptake, despite increasing opioid-related harms and guideline recommendations for use.
Pamela Leece, Triti Khorasheh, Suzanne Zerger, Kim Corace, Lara Nixon, Carol Strike, Ahmed M. Bayomi, Elisabeth Marks, Melissa Holowaty, Frank Crichlow, Sheena Taha, Sharon E. Straus   +11 more
doaj   +1 more source

The Patient Perspective on Injectable Opioid Agonist Treatment: Findings from a Cross-Sectional Interview Study in Two German Cities

THE PATIENT PERSPECTIVE ON INJECTABLE OPIOID AGONIST TREATMENT: FINDINGS FROM A CROSS-SECTIONAL INTERVIEW STUDY IN TWO GERMAN CITIES The Patient Perspective on Injectable Opioid Agonist Treatment: Findings from a Cross-Sectional Interview Study in Two ...
Friedmann, Zoe
core  

Chronic pain treatment experiences and barriers among opioid agonist treatment participants who inject drugs: A qualitative study

Addiction, EarlyView.
Abstract Background and aim Co‐occurring chronic pain affects nearly half of people receiving opioid use disorder (OUD) treatment. Although this pain is often severe, it is usually inadequately managed. Stigma and clinical complexity associated with OUD are thought to further restrict access to pain care.
Jie Yang, Shelley Walker, Amy G. McNeilage, Peter Higgs, Louisa Picco, Paul Dietze, Suzanne Nielsen   +6 more
wiley   +1 more source

Variation in 90‐day substance use disorder‐related acute care events across United States opioid treatment programs: A Medicaid claims analysis

Addiction, EarlyView.
Abstract Background and aims Creating and tracking quality measures has improved outcomes in many areas of healthcare; however, quality measures specific to opioid treatment programs (OTPs) have not yet been developed. Based on the success seen in other fields, introducing quality measures in OTPs should help enhance positive outcomes and decrease ...
Barrett Wallace Montgomery, Tami L. Mark, Thanh Lu, William N. Dowd, Dylan DeLisle, Kathryn N. Burke, Daniel H. Barch, Gary A. Zarkin   +7 more
wiley   +1 more source

Online collection of meeting minutes of the Kansas Prescription Drug and Opioid Advisory Committee's committees, subcommittees and other afiliated groups, 2015-2018.

, 2015
Kansas Prescription Drug and Opioid Advisory Committee and subcommittees and other groups: Diagrams (2 pages) Kansas Prescription Drug and Opioid Advisory Committee.
Kansas Prescription Drug and Opioid Advisory Committee
core   +1 more source

Impacts of decriminalization and its subsequent amendment on drug possession incidents and charges in British Columbia, Canada: Interrupted time series analyses (2013–2024)

Addiction, EarlyView.
Abstract Background and aims Decriminalization of personal possession of select illegal drugs was implemented in British Columbia, Canada, for a three‐year period starting 31 January 2023; however, following perceived increases in public drug use and disorder, an amendment introduced on 7 May 2024 rolled back key provisions.
Jürgen Rehm, Sami Aftab Abdul, Marcos Sanches, Cayley Russell, Farihah Ali, Sameer Imtiaz   +5 more
wiley   +1 more source

Comportamento de coçar e nocicepção evidenciados após a aplicação facial de endotelina-1: um novo teste, uma nova oportunidade farmacológica [PDF]

, 2012
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências Biológicas, Programa de Pós-Graduação em Farmacologia, Florianópolis, 2011O presente trabalho reproduziu o modelo experimental descrito por Shimada e Lamotte, (2008), e o
Gomes, Lenyta Oliveira
core  

Comparison of median, unadjusted mean, and adjusted mean opioid agonist treatment (OAT) duration with concurrent prescription of benzodiazepines, z-drugs, and gabapentinoids, by OAT type.

, 2019
Comparison of median, unadjusted mean, and adjusted mean opioid agonist treatment (OAT) duration with concurrent prescription of benzodiazepines, z-drugs, and gabapentinoids, by OAT type.
John Strang (817558), John Macleod (119316), John Marsden (427925), Tim Millar (3598607), Colin Steer (159192), Rosie Cornish (3426482), Kate Tilling (213507), Matthew Hickman (83053)   +7 more
core   +1 more source

Modelling the wider socio‐economic costs of opioid dependence in the UK

Addiction, EarlyView.
Abstract Background and aims Opioid dependence poses large costs to society, and associated deaths are rising in the United Kingdom (UK) and Europe. Opioid dependence treatment programs combining opioid agonist therapy with psychosocial interventions have been shown to improve treatment retention compared with agonist therapy alone.
George Keel, Susanna Meyner, Daniel Mogford, Mike Burrows, Magnus Värendh, Stojan Zavisic   +5 more
wiley   +1 more source